Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bonvadis is a topical wound care medical device formulated from proprietary natural herbal ingredients. It is clinically proven to accelerate healing across a wide spectrum of wounds, including acute wounds, chronic wounds such as diabetic foot ulcers (DFU), venous and pressure ulcers, post-surgical wounds, and first- and second-degree burns. The product creates an optimal moist microenvironment that resolves chronic inflammation, promotes epithelialization, supports tissue remodeling with minimal scarring, and reduces amputation risk in high-risk patients. Its botanical-based formulation is free from immune rejection risks or proteolytic degradation and has no reported adverse effects. Bonvadis can be used as a standalone treatment or in combination with other wound care modalities such as standard dressings or negative pressure wound therapy[1][2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bonvadis.